Hypothesis

Short, repeatable mRNA‑OSKM delivery, when synchronized with a pulsed NAD⁺‑boosting regimen, activates a PGC‑1α‑dependent mitochondrial repair pathway that uncouples epigenetic age reduction from pluripotency entry and produces organ‑specific rejuvenation without tumor formation.

Rationale

• Partial reprogramming with transient OSKM expression reverses epigenetic age while preserving somatic identity, yet the optimal delivery mode remains undefined. Viral vectors risk integration; chemical cocktails lack precise temporal control. mRNA offers transient, dose‑controllable exposure but has been minimally tested in vivo [3].
• Recent work shows that brief OSKM exposure can stimulate PGC‑1α independently of HIF‑1α‑mediated hypoxia, linking nuclear reprogramming to mitochondrial metabolism (see Front. Cell. Neurosci. 2022).
• NAD⁺ elevation enhances PGC‑α activity and improves mitochondrial fidelity, a manipulation that extends lifespan in model organisms [5]. Combining these two signals may amplify the mitochondrial repair arm of partial reprogramming while keeping the pluripotency trajectory minimal.
• Tissue‑specific responses to OSKM vary, suggesting that metabolic state influences reprogramming outcomes [6]. A NAD⁺ pulse could shift the cellular redox environment, biasing OSKM‑induced transcription toward metabolic rather than stemness programs in a context‑dependent manner.

Predictions

1. Mice receiving cyclic mRNA‑OSKM (4‑day pulses every 28 days) plus intermittent NAD⁺ booster (e.g., nicotinamide riboside 400 mg/kg i.p. 24 h before each OSKM pulse) will show a greater reduction in epigenetic age markers (DNAm clocks) in liver, muscle, and brain than OSKM‑only or NAD⁺‑only groups.
2. Mitochondrial respiration (OXPHOS capacity) and ATP production will increase significantly in treated tissues, accompanied by upregulated PGC‑1α target genes (Tfam, Nrf1, Cox7a1) without a rise in pluripotency markers (Oct4, Nanog) beyond baseline.
3. Incidence of teratomas or tumorigenic lesions will remain at sham‑level rates over a 12‑month observation period, confirming that the combined regimen stays within the "safe window" of partial reprogramming.
4. Benefit magnitude will differ across organs, correlating with baseline NAD⁺ levels and mitochondrial content, allowing prediction of tissue responsiveness from pretreatment metabolomic profiling.

Experimental Design

• Animals: 20‑month‑old C57BL/6J mice, n=10 per group.
• Groups: (1) saline control, (2) mRNA‑OSKM alone (4‑day lipid‑nanoparticle pulse, q4w), (3) NAD⁺ booster alone (NR 400 mg/kg i.p., 24 h before each OSKM pulse), (4) combined mRNA‑OSKM + NAD⁺ booster.
• Readouts: epigenetic age (Horvath mouse clock) at baseline, 3 mo, 6 mo, 9 mo, 12 mo; mitochondrial function (Seahorse OCR, ATP assay); transcriptomics (RNA‑seq) for PGC‑1α pathway and pluripotency genes; histopathology for tumor formation; functional assays (grip strength, treadmill endurance, cognitive maze).
• Statistical plan: Two‑way ANOVA with factors treatment and time, post‑hoc Tukey; survival analysis for tumor incidence.

Potential Outcomes and Interpretation

If the combined group shows superior age‑reversal metrics with enhanced mitochondrial safety and no increase tumorigenicity, the hypothesis is supported, indicating that metabolic priming can steer transient OSKM signaling toward repair rather than dedifferentiation. Lack of added benefit would falsify the premise that NAD⁺‑PGC‑1α coupling amplifies the rejuvenative arm of partial reprogramming. Organ‑specific variation would refine dosing strategies, addressing the tissue‑specificity challenge highlighted in the field.

This approach directly compares mRNA‑based partial reprogramming to existing viral and chemical methods, fills the delivery‑gap noted in the literature, and introduces a mechanistic lever—mitochondrial biogenesis via PGC‑1α—that can be tuned for safer, targeted anti‑aging interventions.

[1] https://www.liebertpub.com/doi/10.1089/cell.2023.0072 [2] https://pubmed.ncbi.nlm.nih.gov/30450724/ [3] https://d-nb.info/1374636274/34 [4] https://www.aging-us.com/article/204896/text [5] https://pmc.ncbi.nlm.nih.gov/articles/PMC12340157/ [6] https://www.fightaging.org/archives/2025/10/a-review-of-the-present-state-of-epigenetic-reprogramming-to-treat-aging/